Watch Ticker

Affimed N.V.

Go to Affimed N.V. Website

$5.16

(%)

Live

Previous Close

$5.16

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$79.9 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach t...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Affimed N.V. - Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology Association (EHA), taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed’s CD16A/CD123-targeting ICE®, AFM28, in an acute myeloid leukemia (AML) mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls.

Related tickers: AFMD.

Read Full Article

Zacks Equity Research - Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates

Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Related tickers: IMTX, AFMD.

Read Full Article

Trending Tickers

FLGC

XNAS

$1.23

(%)

IBIT

XNAS

$39.97

(%)

LASE

XNAS

$2.28

(%)

MGAM

XNAS

$0.00

(%)

MLGO

XNAS

$0.00

(%)